Cardiol Res

Cardiology Research, ISSN 1923-2829 print, 1923-2837 online, Open Access

Article copyright, the authors; Journal compilation copyright, Cardiol Res and Elmer Press Inc

Journal website http://www.cardiologyres.org

Original Article

Volume 10, Number 1, February 2019, pages 34-39

Timing of Coronary Angiography After Successful Fibrinolytic Therapy in ST-Segment Elevated Myocardial Infarction

**Table 1.** Baseline Characteristics of Study Population
Variable	All patients ( n = 76)	Group-1 (n = 29)	Group-2 (n = 47)	P
BP: blood pressure; CAD: coronary artery disease; HDL-C: high density lipoprotein cholesterol; LDLC-C: low density lipoprotein cholesterol; LVEF: left ventricular ejection fraction.
Age (years), (mean ± SD)	56 ± 11.4	54.8 ± 11.2	57.4 ± 11.5	0.354
Female, n, (%)	21 (27.6)	6 (20.7)	15 (31.9)	0.424
Hospitalization time (days)	7.0 ± 4.0	7.3 ± 5.8	6.8 ± 2.4	0.661
Hypertension, n, (%)	27 (35.5)	12 (41.4)	15 (31.9)	0.402
Diabetes mellitus, n, (%)	13 (17.1)	9 (31.0)	4 (8.5)	0.025
Hyperlipidemia, n, (%)	14 (18.4)	4 (13.8)	10 (21.3)	0.414
Current smoker, n, (%)	66 (86.8)	24 (82.8)	42 (89.4)	0.408
History of CAD, n, (%)	9 (11.8)	2 (6.9)	7 (14.9)	0.469
Family history of CAD, n, (%)	17 (22.4)	11 (37.9)	6 (12.8)	0.001
Systolic BP (mm Hg)	137 ± 27	134 ±17	140 ± 32	0.344
Diastolic BP (mm Hg)	80 ± 16	79 ±11	82 ± 19	0.521
Heart rate (per minute)	76 ± 14	73 ±14	78 ± 14	0.176
Hemoglobin (g/dL)	14 ±1.6	14 ±1.4	14 ± 1.7	0.51
Hematocrit (%)	41.3	41.4 ± 3.8	41.3 ± 4.7	0.87
Creatinine (mg/dL)	0.89 ± 0.23	0.91 ± 0.27	0.88 ± 0.2	0.67
Aspartate aminotransferase (U/L)	27.3 ± 20.9	51 ± 92	59 ± 78	0.95
Alanine aminotransferase (U/L)	50.3 ± 83	28 ± 20.3	27 ± 21	0.83
Total cholesterol (mg/dL)	191 ± 40	192 ± 42	191 ± 37	0.93
LDL-C (mg/dL)	121 ± 36	119 ± 34	122 ± 37	0.66
HDL-C (mg/dL)	38 ± 10	38 ± 11	39 ± 9	0.68
Triglyceride (mg/dL)	179 ± 95	194 ± 123	169 ± 74	0.27
LVEF (%)	48.6 ±9.6	53.4 ± 8.7	46.0 ± 9.2	0.003

Table 1. Baseline Characteristics of Study Population

Variable

All patients ( n = 76)

Group-1 (n = 29)

Group-2 (n = 47)

BP: blood pressure; CAD: coronary artery disease; HDL-C: high density lipoprotein cholesterol; LDLC-C: low density lipoprotein cholesterol; LVEF: left ventricular ejection fraction.

Age (years), (mean ± SD)

56 ± 11.4

54.8 ± 11.2

57.4 ± 11.5

0.354

Female, n, (%)

21 (27.6)

6 (20.7)

15 (31.9)

0.424

Hospitalization time (days)

7.0 ± 4.0

7.3 ± 5.8

6.8 ± 2.4

0.661

Hypertension, n, (%)

27 (35.5)

12 (41.4)

15 (31.9)

0.402

Diabetes mellitus, n, (%)

13 (17.1)

9 (31.0)

4 (8.5)

0.025

Hyperlipidemia, n, (%)

14 (18.4)

4 (13.8)

10 (21.3)

0.414

Current smoker, n, (%)

66 (86.8)

24 (82.8)

42 (89.4)

0.408

History of CAD, n, (%)

9 (11.8)

2 (6.9)

7 (14.9)

0.469

Family history of CAD, n, (%)

17 (22.4)

11 (37.9)

6 (12.8)

0.001

Systolic BP (mm Hg)

137 ± 27

134 ±17

140 ± 32

0.344

Diastolic BP (mm Hg)

80 ± 16

79 ±11

82 ± 19

0.521

Heart rate (per minute)

76 ± 14

73 ±14

78 ± 14

0.176

Hemoglobin (g/dL)

14 ±1.6

14 ±1.4

14 ± 1.7

0.51

Hematocrit (%)

41.3

41.4 ± 3.8

41.3 ± 4.7

0.87

Creatinine (mg/dL)

0.89 ± 0.23

0.91 ± 0.27

0.88 ± 0.2

0.67

Aspartate aminotransferase (U/L)

27.3 ± 20.9

51 ± 92

59 ± 78

0.95

Alanine aminotransferase (U/L)

50.3 ± 83

28 ± 20.3

27 ± 21

0.83

Total cholesterol (mg/dL)

191 ± 40

192 ± 42

191 ± 37

0.93

LDL-C (mg/dL)

121 ± 36

119 ± 34

122 ± 37

0.66

HDL-C (mg/dL)

38 ± 10

38 ± 11

39 ± 9

0.68

Triglyceride (mg/dL)

179 ± 95

194 ± 123

169 ± 74

0.27

LVEF (%)

48.6 ±9.6

53.4 ± 8.7

46.0 ± 9.2

0.003

**Table 2.** Procedural Characteristics
Variable	All patients ( n = 76)	Group-1 (n = 29)	Group-2 (n = 47)	P
CAG: coronary angiography; FT: fibrinolytic treatment; PCI: percutaneous coronary intervention.
Symptom onset to first medical contact
< 1 h	47 (61.8)	19 (65.5)	28 (59.6)	0.873
1 - 3 h	23 (30.3)	8 (27.6)	15 (31.9)
> 3 h	6 (7.9)	2 (6.9)	4 (8.5)
Coronary angiography performed	70 (100)	29 (100)	47 (109	NS
Time from FT to CAG	8.86 ± 10.4	2.17 ± 0.38	12.9 ± 11.5	< 0.001
PCI performed	69 (90.8)	26 (89.7)	43 (91.5)	0.788
Femoral access	70 (100)	29 (100)	47 (109	NS

Table 2. Procedural Characteristics

Variable

All patients ( n = 76)

Group-1 (n = 29)

Group-2 (n = 47)

CAG: coronary angiography; FT: fibrinolytic treatment; PCI: percutaneous coronary intervention.

Symptom onset to first medical contact

< 1 h

47 (61.8)

19 (65.5)

28 (59.6)

0.873

1 - 3 h

23 (30.3)

8 (27.6)

15 (31.9)

> 3 h

6 (7.9)

2 (6.9)

4 (8.5)

Coronary angiography performed

70 (100)

29 (100)

47 (109

Time from FT to CAG

8.86 ± 10.4

2.17 ± 0.38

12.9 ± 11.5

< 0.001

PCI performed

69 (90.8)

26 (89.7)

43 (91.5)

0.788

Femoral access

70 (100)

29 (100)

47 (109

**Table 3.** Medication at Discharge and 6 Months Follow-Up
	All patients (n = 76)	Grup-1 (n = 29)	Grup-2 (n = 47)
^aOne patient in Group-2 died at the fourth month. ACEI: angiotensin converting enzyme inhibitor.
Medication at discharge
Aspirin, n, (%)	76 (100)	29 (100)	47 (100)
Clopidogrel, n, (%)	76 (100)	29 (100)	47 (100)
Statins, n, (%)	75 (98)	29 (100)	46 (98)
ACEI, n, (%)	68 (89)	26 (90)	42 (90)
Beta blockers, n, (%)	71 (93)	26 (90)	45 (96)
PPI, n, (%)	68 (89)	28 (96)	40 (85)
Medication at 6 months^a
Aspirin, n, (%)	75 (100)	29 (100)	46 (100)
Clopidogrel, n, (%)	73 (97)	29 (100)	44 (95)
Statins, n, (%)	75 (100)	29 (100)	46 (100)
ACEI, n, (%)	68 (90)	25 (86)	42 (93)
Beta blockers, n, (%)	72 (96)	27 (93)	45 (97)
PPI, n, (%)	68 (90)	25 (86)	43 (95)

Table 3. Medication at Discharge and 6 Months Follow-Up

All patients (n = 76)

Grup-1 (n = 29)

Grup-2 (n = 47)

^aOne patient in Group-2 died at the fourth month. ACEI: angiotensin converting enzyme inhibitor.

Medication at discharge

Aspirin, n, (%)

76 (100)

29 (100)

47 (100)

Clopidogrel, n, (%)

76 (100)

29 (100)

47 (100)

Statins, n, (%)

75 (98)

29 (100)

46 (98)

ACEI, n, (%)

68 (89)

26 (90)

42 (90)

Beta blockers, n, (%)

71 (93)

26 (90)

45 (96)

PPI, n, (%)

68 (89)

28 (96)

40 (85)

Medication at 6 months^a

Aspirin, n, (%)

75 (100)

29 (100)

46 (100)

Clopidogrel, n, (%)

73 (97)

29 (100)

44 (95)

Statins, n, (%)

75 (100)

29 (100)

46 (100)

ACEI, n, (%)

68 (90)

25 (86)

42 (93)

Beta blockers, n, (%)

72 (96)

27 (93)

45 (97)

PPI, n, (%)

68 (90)

25 (86)

43 (95)

**Table 4.** Clinical Outcomes of Short and Long-Term Follow-Up
Variable	All patients ( n = 76)	Group-1 (n = 29)	Group-2 (n = 47)	P
NS: non-significant; MACE: major adverse cardiac events.
Short-term follow-up (6 months)
Death, n, (%)	1 (1.3)	0	1 (2.1)	NS
Re-infarction, n, (%)	7 (9.2)	2 (6.9)	7 (10.6)	0.295
Heart failure, n, (%)	11 (14.5)	3 (10.3)	8 (17)	0.422
MACE, n, (%)	14 (18.4)	4 ( 13.8)	10 (21.3)	0.661
Long- term follow-up (median 57 months)
Death, n, (%)	6 (7.9)	1 (3.4)	5 (10.6)	0.398
Re-infarction, n, (%)	15 (19.7)	5 (17.2)	10 (21.3)	0.668
Heart failure, n, (%)	13 (17.1)	7 (24.1)	6 (12.8)	0.201
MACE, n, (%)	29 (38.2)	11 (37.9)	18 (38.3)	0.974

Table 4. Clinical Outcomes of Short and Long-Term Follow-Up

Variable

All patients ( n = 76)

Group-1 (n = 29)

Group-2 (n = 47)

NS: non-significant; MACE: major adverse cardiac events.

Short-term follow-up (6 months)

Death, n, (%)

1 (1.3)

1 (2.1)

Re-infarction, n, (%)

7 (9.2)

2 (6.9)

7 (10.6)

0.295

Heart failure, n, (%)

11 (14.5)

3 (10.3)

8 (17)

0.422

MACE, n, (%)

14 (18.4)

4 ( 13.8)

10 (21.3)

0.661

Long- term follow-up (median 57 months)

Death, n, (%)

6 (7.9)

1 (3.4)

5 (10.6)

0.398

Re-infarction, n, (%)

15 (19.7)

5 (17.2)

10 (21.3)

0.668

Heart failure, n, (%)

13 (17.1)

7 (24.1)

6 (12.8)

0.201

MACE, n, (%)

29 (38.2)

11 (37.9)

18 (38.3)

0.974